Skip to main content
OpenTrials
Completed

NCT Number: NCT04322461

Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population

A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3 times/week. Cognition and ketones will be assess before and after the intervention, along with endocannabinoids plasma concentrations.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson Disease Acid-Base Imbalance Acidosis Alzheimer Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Dementia Ketosis Mental Disorders Metabolic Diseases Movement Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Nutritional and Metabolic Diseases Parkinsonian Disorders Synucleinopathies Tauopathies

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre de recherche sur le vieillissement

Sherbrooke, Quebec, J1H 4C4, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Alzheimer's or parkinson disease diagnostic
  • Stable medication associated with the disease
  • Able to consent
  • Presence of an accompanying person for the first and last visit.
  • Ability to read and talk in French

Exclusion criteria

  • MMSE < 20
  • MCT or coconut oil supplementation
  • Coconut allergy
  • Cannabis, THC or CBD consumption
  • Excessive alcohol consumption
  • Physical activity 3x/week
  • Presence of an metallic object in the body
  • Impossibility to lay in dorsal decubitus for 40 minutes
  • Cardiac disease
  • Any uncontrolled disease that could interfer with the project.

Treatment and study plan

Betaquik MCT supplement

Dietary Supplement

50g/day divided in 3. Breakfast, lunch and dinner

Primary outcomes

  1. Cognition

    Time frame: 2 months, evaluation before and after intervention

    Measure of cognition with CANTAB

  2. Ketones

    Time frame: 2 months, evaluation before and after intervention

    Measurement of ketones concentrations

Secondary outcomes

  1. Endocannabinoids

    Time frame: 2 months, evaluation before and after intervention

    Endocannabinoids plasma concentration

Sponsors and collaborators

Lead sponsor

Université de Sherbrooke

Other

Collaborators

  • Société des Produits Nestlé (SPN)

Registry information

Official study title

Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population : Pilot Project PARKA

Acronym: PARKA

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Mar 26, 2020
Registry last updated
Jun 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.